Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval.
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations. Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout.
No Fear And No Panic After A 10% Correction = No Bottom In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals. NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases. Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation.
Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.
